drugset / Trial / NCT00888329

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

NCT00888329

Phase 4 Terminated 256 enrolled Mayo Clinic
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.

Timeline

Start
2007-07
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 40 mg Oral

Indications

No indication recorded.